Gesynta Pharma AB
↗Stockholm, Sweden
Gesynta Pharma AB is a Swedish clinical-stage biopharmaceutical company focused on developing first-in-class oral therapies for chronic inflammatory diseases. The company's research is centered on the enzyme microsomal prostaglandin E synthase-1 (mPGES-1), a key driver of inflammation and pain. By selectively inhibiting this enzyme, Gesynta aims to provide potent anti-inflammatory and pain-relieving effects without the side effects associated with traditional NSAIDs or hormonal treatments.
Originally spun out from research at the Karolinska Institutet, the company has pivoted its lead candidate, vipoglanstat, from systemic sclerosis to endometriosis following Phase 2 exploratory data. The company is currently advancing a pipeline of small molecule inhibitors targeting high unmet needs in women's health and chronic pain management.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Inflammatory & Rare Diseases
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M-$1M
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$67.2M
Investors:Innovestor Life Science, HealthCap, Hadean Ventures, Industrifonden, Linc, Catalyze Capital, Amboy Street Ventures, Foreground Capital, SEB Venture Capital
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Orexo AB (Acquisition of the OX-MPI development program/GS-248), Karolinska Institutet (Academic research origin)
COMPETITION
Position:Emerging
Competitors:AbbVie (Orilissa), Neurocrine Biosciences, Myovant Sciences, Hope Medicine, Nippon Shinyaku, Theramex
LEADERSHIP
Key Executives:
Patric Stenberg - CEO & Co-founder
Eva Johnsson - Chief Medical Officer
Charlotte Edenius - VP R&D Strategy & Co-founder
Scientific Founders:Per-Johan Jakobsson, Patric Stenberg, Charlotte Edenius, Gunilla Ekström
Board Members:Roger Franklin (Chairman, Hadean Ventures), David Colpman, Cristina Csimma, Kristina Ekberg (HealthCap), Jonas Jendi (Industrifonden), Pekka Simula (Innovestor)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Gesynta Pharma AB and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Gesynta Pharma AB. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.